“The United States is one of the strategic markets for Antibiotice’s international development, currently contributing approximately by 15% to the company’s exports. At the end of May 2026, Antibiotice’s main distributor in the US successfully completed audit carried out at the company’s production facilities in lași, reconfirming its compliance with the high quality and compliance standards imposed by the American the market.

The audit result validates the continuity of a strategic partnership developed over 13 years, constantly strengthened by increasing the volumes sold. After the temporary adjustment recorded in 2025, driven by uncertainties in the commercial and regulatory environment, Antibiotice’s exports to the United States returned to an upward trend in 2026, resuming the positive dynamics characteristic of the 2020-2024 period. In the context of stabilizing market conditions and maintaining solid demand for critical medicines, Antibiotice estimates an increase of approximately 25% in its sales of finished products to the American market in 2026 compared to the previous year. This development supports favorable prospects for strengthening Antibiotice’s position on one of the most important and demanding pharmaceutical markets in the world,” the report reads.

According to the report, “the entry on the Spanish market with cardiovascular medicines Antibiotice is also enhancing its presence on the European market by entering the Spanish market, one of the most competitive pharmaceutical markets in Europe. The company will introduce three medicinal products for the treatment of cardiovascular diseases on the Spanish market through a reference partner in the Spanish pharmaceutical retail.

At the end of 2025, the export sales accounted for approximately 41% of Antibiotice’s turnover, confirming the strategic role of foreign markets  in the company’s development. After the first quarter of 2026, the sales of finished products and active substances reached USD15.8 million, a level close to that recorded in the previous year, despite an international context experiencing heightened volatility, pricing pressure and increasing operational costs.

The upward trend in sales in the United States, the expansion of the company’s presence in Europe – a region that currently generates approximately 50% of finished product, as well as the continuous development of the international project portfolio, support favorable prospects for speeding up the company’s external development and strengthening the value created for shareholders in the long term.”